Need help finding what you are looking for?
Contact Us
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223398
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223398
Global Brain Cancer Diagnostic Market - Industry Trends and Forecast to 2030
PUBLISHED:
PAGES: 248 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Global brain cancer diagnostic market is projected to register a substantial CAGR of 18.9 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa), Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the global brain cancer diagnostic market are:
Rising cases of brain cancer worldwide
Rising awareness of early diagnosis of brain cancer
Improved imaging techniques
Innovations in drug delivery to brain cancer cells
Market Players
Some of the key market players for the global brain cancer diagnostic market are listed below:
NIHON KOHDEN CORPORATION.
FUJIFILM Holdings Corporation
GE HealthCare
Koninklijke Philips N.V.
BD
Siemens Healthcare GmbH
Canon Inc.
Others
TABLE OF CONTENTS
1 INTRODUCTION 25
- 1.1 OBJECTIVES OF THE STUDY 25
- 1.2 MARKET DEFINITION 25
- 1.3 OVERVIEW OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET 25
- 1.4 CURRENCY AND PRICING 27
- 1.5 LIMITATIONS 27
- 1.6 MARKETS COVERED 27
2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 30
- 2.1 MARKETS COVERED 30
- 2.2 GEOGRAPHICAL SCOPE 31
- 2.3 YEARS CONSIDERED FOR THE STUDY 32
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
- 2.6 MULTIVARIATE MODELLING 37
- 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 37
- 2.8 DBMR MARKET POSITION GRID 38
- 2.9 VENDOR SHARE ANALYSIS 40
- 2.10 MARKET END USER COVERAGE GRID 41
- 2.11 SECONDARY SOURCES 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
- 4.1 PESTEL ANALYSIS 48
- 4.2 PORTER'S FIVE FORCES 49
5 EPIDEMIOLOGY 50
6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 51
7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 52
- 7.1 REGULATORY SCENARIO IN THE U.S 52
- 7.2 REGULATORY SCENARIO IN AUSTRALIA 53
- 7.3 REGULATORY SCENARIO IN JAPAN 53
- 7.4 REGULATORY SCENARIO IN CHINA 53
8 MARKET OVERVIEW 55
- 8.1 DRIVERS 57
- 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 57
- 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 57
- 8.1.3 IMPROVED IMAGING TECHNIQUES 58
- 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 58
- 8.2 RESTRAINTS 59
- 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 59
- 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 59
- 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 60
- 8.3 OPPORTUNITIES 60
- 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 60
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 60
- 8.3.3 RISING HEALTHCARE EXPENDITURE 61
- 8.4 CHALLENGES 62
- 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 62
- 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 62
9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 63
- 9.1 OVERVIEW 64
- 9.2 IMAGING TEST 67
- 9.2.1 CT SCAN 68
- 9.2.2 MRI 68
- 9.2.3 PET 68
- 9.2.4 OTHERS 68
- 9.3 MOLECULAR TESTING 69
- 9.4 ELECTROENCEPHALOGRAPHY (EEG) 69
- 9.5 LUMBAR PUNCTURE 70
- 9.6 BIOPSY 71
- 9.6.1 OPEN BIOPSY 72
- 9.6.2 STEREOTACTIC BIOPSY 72
- 9.6.3 NEEDLE BIOPSY 72
- 9.6.4 NEUROENDOSCOPY 72
- 9.7 OTHERS 72
10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 73
- 10.1 OVERVIEW 74
- 10.2 GLIOBLASTOMA MULTIFORME 77
- 10.3 MENINGIOMAS 78
- 10.4 ASTROCYTOMAS 79
- 10.5 ACOUSTIC NEUROMA 80
- 10.6 OLIGODENDROGLIOMA 81
- 10.7 OLIGODENDROGLIOMA 81
- 10.8 OTHERS 82
11 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 83
- 11.1 OVERVIEW 84
- 11.2 35-65 87
- 11.3 65 AND ABOVE 88
- 11.4 BELOW 21 89
- 11.5 21-34 90
12 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 91
- 12.1 OVERVIEW 92
- 12.2 HOSPITALS 95
- 12.3 SPECIALTY CLINICS 96
- 12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 97
- 12.5 AMBULATORY SURGICAL CENTERS 98
- 12.6 OTHERS 99
13 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 100
- 13.1 OVERVIEW 101
- 13.2 NORTH AMERICA 106
- 13.2.1 U.S. 113
- 13.2.2 CANADA 115
- 13.2.3 MEXICO 117
- 13.3 EUROPE 119
- 13.3.1 GERMANY 126
- 13.3.2 FRANCE 128
- 13.3.3 U.K. 130
- 13.3.4 ITALY 132
- 13.3.5 SPAIN 134
- 13.3.6 RUSSIA 136
- 13.3.7 SWITZERLAND 138
- 13.3.8 NETHERLANDS 140
- 13.3.9 TURKEY 142
- 13.3.10 BELGIUM 144
- 13.3.11 REST OF EUROPE 146
- 13.4 ASIA-PACIFIC 147
- 13.4.1 CHINA 154
- 13.4.2 JAPAN 156
- 13.4.3 INDIA 158
- 13.4.4 AUSTRALIA 160
- 13.4.5 SOUTH KOREA 162
- 13.4.6 THAILAND 164
- 13.4.7 SINGAPORE 166
- 13.4.8 INDONESIA 168
- 13.4.9 MALAYSIA 170
- 13.4.10 PHILIPPINES 172
- 13.4.11 REST OF ASIA-PACIFIC 174
- 13.5 SOUTH AMERICA 175
- 13.5.1 BRAZIL 182
- 13.5.2 ARGENTINA 184
- 13.5.3 REST OF SOUTH AMERICA 186
- 13.6 MIDDLE EAST AND AFRICA 187
- 13.6.1 SOUTH AFRICA 194
- 13.6.2 SAUDI ARABIA 196
- 13.6.3 U.A.E. 198
- 13.6.4 KUWAIT 200
- 13.6.5 EGYPT 202
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 204
14 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 205
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 205
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 206
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 207
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 208
15 SWOT ANALYSIS 209
16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 210
- 16.1 KONINKLIJKE PHILIPS N.V. 210
- 16.1.1 COMPANY SNAPSHOT 210
- 16.1.2 REVENUE ANALYSIS 210
- 16.1.3 COMPANY SHARE ANALYSIS 211
- 16.1.4 PRODUCT PORTFOLIO 211
- 16.1.5 RECENT DEVELOPMENTS 212
- 16.2 CANON INC. 213
- 16.2.1 COMPANY SNAPSHOT 213
- 16.2.2 REVENUE ANALYSIS 213
- 16.2.3 COMPANY SHARE ANALYSIS 214
- 16.2.4 PRODUCT PORTFOLIO 214
- 16.2.5 RECENT DEVELOPMENT 214
- 16.3 SIEMENS HEALTHCARE GMBH 215
- 16.3.1 COMPANY SNAPSHOT 215
- 16.3.2 REVENUE ANALYSIS 216
- 16.3.3 COMPANY SHARE ANALYSIS 216
- 16.3.4 PRODUCT PORTFOLIO 217
- 16.3.5 RECENT DEVELOPMENTS 217
- 16.4 BD 218
- 16.4.1 COMPANY SNAPSHOT 218
- 16.4.2 REVENUE ANALYSIS 219
- 16.4.3 COMPANY SHARE ANALYSIS 219
- 16.4.4 PRODUCT PORTFOLIO 220
- 16.4.5 RECENT DEVELOPMENTS 220
- 16.5 NIHON KOHDEN CORPORATION. 221
- 16.5.1 COMPANY SNAPSHOT 221
- 16.5.2 RECENT FINANCIALS 221
- 16.5.3 COMPANY SHARE ANALYSIS 222
- 16.5.4 PRODUCT PORTFOLIO 222
- 16.5.5 RECENT DEVELOPMENT 222
- 16.6 BIOCEPT, INC. 223
- 16.6.1 COMPANY SNAPSHOT 223
- 16.6.2 REVENUE ANALYSIS 223
- 16.6.3 PRODUCT PORTFOLIO 224
- 16.6.4 RECENT DEVELOPMENT 224
- 16.7 BIOMIND 225
- 16.7.1 COMPANY SNAPSHOT 225
- 16.7.2 PRODUCT PORTFOLIO 225
- 16.7.3 RECENT DEVELOPMENT 225
- 16.8 CEREBRAL DIAGNOSTIC 226
- 16.8.1 COMPANY SNAPSHOT 226
- 16.8.2 PRODUCT PORTFOLIO 226
- 16.8.3 RECENT DEVELOPMENT 226
- 16.9 DXCOVER LIMITED 227
- 16.9.1 COMPANY SNAPSHOT 227
- 16.9.2 PRODUCT PORTFOLIO 227
- 16.9.3 RECENT DEVELOPMENT 227
- 16.10 FONAR CORP. 228
- 16.10.1 COMPANY SNAPSHOT 228
- 16.10.2 REVENUE ANALYSIS 228
- 16.10.3 PRODUCT PORTFOLIO 229
- 16.10.4 RECENT DEVELOPMENT 229
- 16.11 FUJIFILM CORPORATION 230
- 16.11.1 COMPANY SNAPSHOT 230
- 16.11.2 REVENUE ANALYSIS 230
- 16.11.3 PRODUCT PORTFOLIO 231
- 16.11.4 RECENT DEVELOPMENT 231
- 16.12 GE HEALTHCARE. 232
- 16.12.1 COMPANY SNAPSHOT 232
- 16.12.2 REVENUE ANALYSIS 232
- 16.12.3 PRODUCT PORTFOLIO 233
- 16.12.4 RECENT DEVELOPMENT 233
- 16.13 HITACHI, LTD. 234
- 16.13.1 COMPANY SNAPSHOT 234
- 16.13.2 REVENUE ANALYSIS 234
- 16.13.3 PRODUCT PORTFOLIO 235
- 16.13.4 RECENT DEVELOPMENT 235
- 16.14 MINFOUND MEDICAL SYSTEMS CO., 236
- 16.14.1 COMPANY SNAPSHOT 236
- 16.14.2 PRODUCT PORTFOLIO 236
- 16.14.3 RECENT DEVELOPMENT 236
- 16.15 NANTOMICS. 237
- 16.15.1 COMPANY SNAPSHOT 237
- 16.15.2 PRODUCT PORTFOLIO 237
- 16.15.3 RECENT DEVELOPMENT 237
- 16.16 NEUSOFT CORPORATION 238
- 16.16.1 COMPANY SNAPSHOT 238
- 16.16.2 REVENUE ANALYSIS 238
- 16.16.3 PRODUCT PORTFOLIO 239
- 16.16.4 RECENT DEVELOPMENT 239
- 16.17 SEQUOIA HEALTHCARE. 240
- 16.17.1 COMPANY SNAPSHOT 240
- 16.17.2 PRODUCT PORTFOLIO 240
- 16.17.3 RECENT DEVELOPMENT 240
- 16.18 STERNMED GMBH 241
- 16.18.1 COMPANY SNAPSHOT 241
- 16.18.2 PRODUCT PORTFOLIO 241
- 16.18.3 RECENT DEVELOPMENT 241
- 16.19 THERMO FISHER SCIENTIFIC INC. 242
- 16.19.1 COMPANY SNAPSHOT 242
- 16.19.2 REVENUE ANALYSIS 242
- 16.19.3 PRODUCT PORTFOLIO 243
- 16.19.4 RECENT DEVELOPMENT 243
- 16.20 TIME MEDICAL HOLDING. 244
- 16.20.1 COMPANY SNAPSHOT 244
- 16.20.2 PRODUCT PORTFOLIO 244
- 16.20.3 RECENT DEVELOPMENTS 244
17 QUESTIONNAIRE 245
18 RELATED REPORTS 248
LIST OF TABLES
- TABLE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 66
- TABLE 2 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
- TABLE 3 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
- TABLE 4 GLOBAL MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
- TABLE 5 GLOBAL ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
- TABLE 6 GLOBAL LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
- TABLE 7 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 71
- TABLE 8 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 71
- TABLE 9 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 72
- TABLE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 76
- TABLE 11 GLOBAL GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
- TABLE 12 GLOBAL MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
- TABLE 13 GLOBAL ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 79
- TABLE 14 GLOBAL ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 80
- TABLE 15 GLOBAL OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 81
- TABLE 16 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 82
- TABLE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 86
- TABLE 18 GLOBAL 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
- TABLE 19 GLOBAL 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 88
- TABLE 20 GLOBAL BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 89
- TABLE 21 GLOBAL 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 90
- TABLE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 94
- TABLE 23 GLOBAL HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 95
- TABLE 24 GLOBAL SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 96
- TABLE 25 GLOBAL DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 97
- TABLE 26 GLOBAL AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 98
- TABLE 27 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 99
- TABLE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 105
- TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 110
- TABLE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
- TABLE 31 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
- TABLE 32 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
- TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 111
- TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 111
- TABLE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 112
- TABLE 36 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
- TABLE 37 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
- TABLE 38 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
- TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 114
- TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 114
- TABLE 41 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 114
- TABLE 42 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
- TABLE 43 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
- TABLE 44 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
- TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 116
- TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 116
- TABLE 47 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 116
- TABLE 48 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
- TABLE 49 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
- TABLE 50 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
- TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 118
- TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 118
- TABLE 53 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 118
- TABLE 54 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 123
- TABLE 55 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
- TABLE 56 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
- TABLE 57 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
- TABLE 58 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 124
- TABLE 59 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 125
- TABLE 60 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 125
- TABLE 61 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
- TABLE 62 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
- TABLE 63 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
- TABLE 64 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 127
- TABLE 65 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 127
- TABLE 66 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 127
- TABLE 67 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
- TABLE 68 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
- TABLE 69 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
- TABLE 70 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 129
- TABLE 71 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 129
- TABLE 72 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 129
- TABLE 73 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
- TABLE 74 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
- TABLE 75 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
- TABLE 76 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
- TABLE 77 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 131
- TABLE 78 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 131
- TABLE 79 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
- TABLE 80 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
- TABLE 81 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
- TABLE 82 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 133
- TABLE 83 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 133
- TABLE 84 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 133
- TABLE 85 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
- TABLE 86 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
- TABLE 87 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
- TABLE 88 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 135
- TABLE 89 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 135
- TABLE 90 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 135
- TABLE 91 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
- TABLE 92 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
- TABLE 93 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
- TABLE 94 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 137
- TABLE 95 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 137
- TABLE 96 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 137
- TABLE 97 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
- TABLE 98 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
- TABLE 99 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
- TABLE 100 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 139
- TABLE 101 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 139
- TABLE 102 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 139
- TABLE 103 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
- TABLE 104 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
- TABLE 105 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
- TABLE 106 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
- TABLE 107 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 141
- TABLE 108 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 141
- TABLE 109 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
- TABLE 110 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
- TABLE 111 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
- TABLE 112 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
- TABLE 113 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 143
- TABLE 114 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 143
- TABLE 115 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
- TABLE 116 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
- TABLE 117 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
- TABLE 118 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 145
- TABLE 119 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 145
- TABLE 120 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 145
- TABLE 121 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
- TABLE 122 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 151
- TABLE 123 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
- TABLE 124 ASIA-PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
- TABLE 125 ASIA-PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
- TABLE 126 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 152
- TABLE 127 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 153
- TABLE 128 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 153
- TABLE 129 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
- TABLE 130 CHINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
- TABLE 131 CHINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
- TABLE 132 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 155
- TABLE 133 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 155
- TABLE 134 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 155
- TABLE 135 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
- TABLE 136 JAPAN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
- TABLE 137 JAPAN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
- TABLE 138 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 157
- TABLE 139 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 157
- TABLE 140 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 157
- TABLE 141 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
- TABLE 142 INDIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
- TABLE 143 INDIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
- TABLE 144 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 159
- TABLE 145 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 159
- TABLE 146 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 159
- TABLE 147 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
- TABLE 148 AUSTRALIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
- TABLE 149 AUSTRALIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
- TABLE 150 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 161
- TABLE 151 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 161
- TABLE 152 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 161
- TABLE 153 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
- TABLE 154 SOUTH KOREA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
- TABLE 155 SOUTH KOREA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
- TABLE 156 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 163
- TABLE 157 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 163
- TABLE 158 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 163
- TABLE 159 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
- TABLE 160 THAILAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
- TABLE 161 THAILAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
- TABLE 162 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 165
- TABLE 163 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 165
- TABLE 164 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 165
- TABLE 165 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
- TABLE 166 SINGAPORE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
- TABLE 167 SINGAPORE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
- TABLE 168 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 167
- TABLE 169 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 167
- TABLE 170 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 167
- TABLE 171 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
- TABLE 172 INDONESIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
- TABLE 173 INDONESIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
- TABLE 174 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 169
- TABLE 175 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 169
- TABLE 176 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 169
- TABLE 177 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
- TABLE 178 MALAYSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
- TABLE 179 MALAYSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
- TABLE 180 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 171
- TABLE 181 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 171
- TABLE 182 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 171
- TABLE 183 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
- TABLE 184 PHILIPPINES IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
- TABLE 185 PHILIPPINES BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
- TABLE 186 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 173
- TABLE 187 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 173
- TABLE 188 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 173
- TABLE 189 REST OF ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 174
- TABLE 190 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 179
- TABLE 191 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
- TABLE 192 SOUTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
- TABLE 193 SOUTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
- TABLE 194 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 180
- TABLE 195 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 180
- TABLE 196 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 181
- TABLE 197 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
- TABLE 198 BRAZIL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
- TABLE 199 BRAZIL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
- TABLE 200 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 183
- TABLE 201 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 183
- TABLE 202 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 183
- TABLE 203 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
- TABLE 204 ARGENTINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
- TABLE 205 ARGENTINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
- TABLE 206 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 185
- TABLE 207 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 185
- TABLE 208 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 185
- TABLE 209 REST OF SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 186
- TABLE 210 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 191
- TABLE 211 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
- TABLE 212 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
- TABLE 213 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
- TABLE 214 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 192
- TABLE 215 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 192
- TABLE 216 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 193
- TABLE 217 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
- TABLE 218 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
- TABLE 219 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
- TABLE 220 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 195
- TABLE 221 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 195
- TABLE 222 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 195
- TABLE 223 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
- TABLE 224 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
- TABLE 225 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
- TABLE 226 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 197
- TABLE 227 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 197
- TABLE 228 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 197
- TABLE 229 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
- TABLE 230 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
- TABLE 231 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
- TABLE 232 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 199
- TABLE 233 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 199
- TABLE 234 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 199
- TABLE 235 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
- TABLE 236 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
- TABLE 237 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
- TABLE 238 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 201
- TABLE 239 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 201
- TABLE 240 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 201
LIST OF FIGURES
- FIGURE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 30
- FIGURE 2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 33
- FIGURE 3 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 34
- FIGURE 4 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 35
- FIGURE 5 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 35
- FIGURE 6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 36
- FIGURE 7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 38
- FIGURE 8 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 40
- FIGURE 9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 41
- FIGURE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 44
- FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 45
- FIGURE 12 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 46
- FIGURE 13 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 46
- FIGURE 14 ASIA -PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR FOR BRAIN CANCER DIAGNOSTIC MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 47
- FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET 56
- FIGURE 16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 64
- FIGURE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 65
- FIGURE 18 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 65
- FIGURE 19 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 66
- FIGURE 20 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 74
- FIGURE 21 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 75
- FIGURE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 75
- FIGURE 23 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 76
- FIGURE 24 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 84
- FIGURE 25 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 85
- FIGURE 26 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 85
- FIGURE 27 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 86
- FIGURE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 92
- FIGURE 29 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 93
- FIGURE 30 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 93
- FIGURE 31 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 94
- FIGURE 32 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 102
- FIGURE 33 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022) 103
- FIGURE 34 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2023 & 2030) 103
- FIGURE 35 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022 & 2030) 104
- FIGURE 36 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 104
- FIGURE 37 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 107
- FIGURE 38 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 108
- FIGURE 39 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 108
- FIGURE 40 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 109
- FIGURE 41 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 109
- FIGURE 42 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 120
- FIGURE 43 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 121
- FIGURE 44 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 121
- FIGURE 45 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 122
- FIGURE 46 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 122
- FIGURE 47 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 148
- FIGURE 48 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 149
- FIGURE 49 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 149
- FIGURE 50 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 150
- FIGURE 51 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 150
- FIGURE 52 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 176
- FIGURE 53 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 177
- FIGURE 54 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 177
- FIGURE 55 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 178
- FIGURE 56 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 178
- FIGURE 57 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 188
- FIGURE 58 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 189
- FIGURE 59 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 189
- FIGURE 60 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 190
- FIGURE 61 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 190
- FIGURE 62 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 205
- FIGURE 63 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 206
- FIGURE 64 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 207
- FIGURE 65 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 208
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.